BAY63-2521 - 慢性血栓塞栓性肺高血圧症患者を対象とした長期延長試験

基本情報

NCT ID

NCT00910429

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

237

治験依頼者名

Bayer

概要

Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521. The aim of the long term study is to collect additional information to evaluate the safety and tolerability of BAY63-2521. Patients will be treated with open label medication on their individual optimal dose between 0,5 mg - 2,5 mg tid.

対象疾患

介入

依頼者（Sponsor）